{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:45:06Z","timestamp":1765547106745,"version":"3.40.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.eclinm.2023.102195","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T20:05:41Z","timestamp":1694203541000},"page":"102195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial"],"prefix":"10.1016","volume":"64","author":[{"given":"Suad","family":"Hannawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-0774","authenticated-orcid":false,"given":"Linda","family":"Saf Eldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-0777","authenticated-orcid":false,"given":"Alaa","family":"Abuquta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alamadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aala","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuige","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlin","family":"Gai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2023.102195_bib2","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1038\/s41467-022-32396-9","article-title":"Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection","volume":"13","author":"Khan","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102195_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1473-3099(23)00060-9","article-title":"Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study","volume":"23","author":"Tan","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102195_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1473-3099(22)00805-2","article-title":"Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection","volume":"23","author":"Jiang","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102195_bib5","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1038\/s41467-022-31838-8","article-title":"Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections","volume":"13","author":"Andeweg","year":"2022","journal-title":"Nat Commun"},{"issue":"69","key":"10.1016\/j.eclinm.2023.102195_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102195_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102195_bib8","article-title":"mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant","volume":"3","author":"Edara","year":"2022","journal-title":"Cell Rep Med"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102195_bib9","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102195_bib10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study [published correction appears in Lancet Infect Dis. 2022 Sep;22(9):e239]","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102195_bib11","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jmv.27515","article-title":"Omicron variant genome evolution and phylogenetics","volume":"94","author":"Kandeel","year":"2022","journal-title":"J\u00a0Med Virol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102195_bib12","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/jmv.27532","article-title":"SARS-CoV-2 omicron variant: could it be another threat?","volume":"94","author":"Shanmugaraj","year":"2022","journal-title":"J\u00a0Med Virol"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102195_bib13","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","article-title":"Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine against COVID-19: a phase 2\/3 trial","volume":"28","author":"Chalkias","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.eclinm.2023.102195_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A\u00a0bivalent Omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102195_bib15","article-title":"Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant","author":"Scheaffer","year":"2022","journal-title":"bioRxiv [Preprint]"},{"author":"Swanson","key":"10.1016\/j.eclinm.2023.102195_bib16"},{"key":"10.1016\/j.eclinm.2023.102195_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virol.2022.09.003","article-title":"Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants","volume":"576","author":"Wang","year":"2022","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102195_bib18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/vaccines10050702","article-title":"A\u00a0bivalent COVID-19 vaccine based on alpha and beta variants elicits potent and broad immune responses in mice against SARS-CoV-2 variants","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102195_bib19","first-page":"154","article-title":"Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: a randomized, double-blinded, placebo-controlled, phase I clinical trial","volume":"86","author":"Wang","year":"2022","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.eclinm.2023.102195_bib20","article-title":"Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1\/2 clinical trial","volume":"87","author":"Hannawi","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102195_bib21","first-page":"154","article-title":"Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: a randomized, double-blind, placebo-controlled phase 1\/2 clinical trial","volume":"86","author":"Hannawi","year":"2022","journal-title":"J\u00a0Infect"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102195_bib22","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s11427-022-2207-7","article-title":"A\u00a0spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants","volume":"66","author":"Wang","year":"2022","journal-title":"Sci China Life Sci"},{"issue":"10324","key":"10.1016\/j.eclinm.2023.102195_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102195_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83694","article-title":"Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial","volume":"12","author":"Thakkar","year":"2023","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102195_bib25","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/s41467-022-31379-0","article-title":"Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial","volume":"13","author":"Kaabi","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102195_bib26","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMc2119426","article-title":"Effects of a prolonged booster interval on neutralization of Omicron variant","volume":"386","author":"Zhao","year":"2022","journal-title":"N\u00a0Engl J Med"},{"year":"2007","series-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","key":"10.1016\/j.eclinm.2023.102195_bib27"},{"key":"10.1016\/j.eclinm.2023.102195_bib28","article-title":"Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2","volume":"150\u2013151","author":"Mahmoud","year":"2022","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.eclinm.2023.102195_bib29","article-title":"Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine: an interim analysis","author":"Toback","year":"2023","journal-title":"medRxiv [Preprint]"},{"key":"10.1016\/j.eclinm.2023.102195_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijid.2021.09.073","article-title":"Performance of the T-SPOT\u24c7.COVID test for detecting SARS-CoV-2-responsive T cells","volume":"113","author":"Kruse","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102195_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1473-3099(22)00800-3","volume":"23","author":"Fadlyana","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102195_bib32","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.vaccine.2023.01.032","article-title":"Safety and efficacy of COVID-19 prime-boost vaccinations: homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals","volume":"41","author":"Mallah","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102195_bib33","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41467-022-29477-0","article-title":"Neutralizing activity of BBIBP-CorV vaccine-elicited sera against beta, delta and other SARS-CoV-2 variants of concern","volume":"13","author":"Yu","year":"2022","journal-title":"Nat Commun"},{"issue":"10296","key":"10.1016\/j.eclinm.2023.102195_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. [published correction appears in Lancet. 2022 Jan 29;399(10323):436]","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102195_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomized, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102195_bib36","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102195_bib37","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"6576","key":"10.1016\/j.eclinm.2023.102195_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102195_bib39","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/vaccines10091548","article-title":"Antibody titers and protection against Omicron (BA.1 and BA.2) SARS-CoV-2 infection","volume":"10","author":"Dimeglio","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.eclinm.2023.102195_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2023.105411","article-title":"Combined epidemiology and genetic sequencing surveillance in the era of COVID-19 pandemic; Abu Dhabi experience, United Arab Emirates","volume":"109","author":"Abuyadek","year":"2023","journal-title":"Infect Genet Evol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:34:44Z","timestamp":1732088084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023003723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":39,"alternative-id":["S2589537023003723"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102195","relation":{},"ISSN":["2589-5370"],"issn-type":[{"type":"print","value":"2589-5370"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102195"}}